- HTG Molecular Diagnostics ( NASDAQ: HTGM ) stock rose ~30% premarket on Tuesday after the company closed a public offering on Dec. 23 to raise ~$10M in gross proceeds.
- The company offered ~1.29M common shares (or pre-funded warrants in lieu thereof), Series A-1 warrants to buy up to ~1.29M shares and Series A-2 warrants to purchase ~1.29M common stock, at a combined offering price of $7.75 per share (or pre-funded warrant) and accompanying warrants.
- The Series A-1 warrants and the Series A-2 warrants, each have an exercise price of $7.50 per share, respectively.
- The company plans to use the net proceeds — expected ~$8.7M — for general corporate purposes, which may include research and development, clinical trial and capital expenditures.
- HTGM +29.35% to $4.01 premarket Dec. 27
For further details see:
HTG Molecular surges ~30% on closing $10M stock, warrants offering